# A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis

> **NCT03161457** · PHASE1 · TERMINATED · sponsor: **JHL Biotech, Inc.** · enrollment: 153 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Arthritis, Rheumatoid

## Interventions

- **BIOLOGICAL:** JHL1101
- **BIOLOGICAL:** MabThera

## Key facts

- **NCT ID:** NCT03161457
- **Lead sponsor:** JHL Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-27
- **Primary completion:** 2019-04-16
- **Final completion:** 2019-04-16
- **Target enrollment:** 153 (ACTUAL)
- **Why stopped:** The development was stopped due to company's strategy consideration
- **Last updated:** 2020-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03161457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03161457, "A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03161457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*